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Abstract 
Background: The National Review of Asthma Deaths UK highlighted that 46% of deaths could be avoided and 
recommended that all sufferers receive a structured asthma annual review which assess asthma control. In primary 
care this is commonly achieved using symptom-based questionnaires such as the Asthma Control Test (ACT). A 
newer method of assessing asthma control is Fractional Exhaled Nitric Oxide (FeNO) testing, which is currently 
recommended for the diagnosis of asthma, but not for monitoring of asthma control. The study aim was to assess the 
correlation between self-reported symptoms as measured by the ACT and FeNO testing and the subsequent impact 
of FeNO testing on prescribing of asthma medication.
Methods: A retrospective review of 65 patients who had received both ACT and FeNO testing as part of their asthma 
annual review. A spearman correlation was used to estimate the correlation between ACT scores and FENO levels. A 
χ2 test was used to compare prompting frequency of the measures and Kendalls τ statistic was made to estimate their 
concordance and influence on subsequent ICS medication prescription.
Results: The mean age of the participants was 41 years (4–93 years). There was no statistically significant correlation 
between ACT and FeNO (ρ = 0.195, p = 0.120). The median FeNO was 26 ppb (range 8–279 ppb), and the ACT score 
20 (range 5 to 25 points). Furthermore, FeNO more frequently prompts a change in medication than ACT, 66% versus 
42% (p = 0.005). A low concordance between the measures was found (Kendall’s τ statistic − 0.321).
Conclusion: FeNO should be considered for monitoring of control in asthma. To balance the cost of implementing 
this technology into primary care a risk stratified approach could be applied to testing.
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Background
Asthma is a serious global health problem affecting all age 
groups. The prevalence is high in the UK with 5.4 million 
people receiving treatment for asthma, which includes 
1.1 million children. The UK has the third highest death 
rates for asthma in high-income countries worldwide, 
with 1370 asthma across the UK in 2016 [1]. In the 
National Review of Asthma Deaths UK (NRAD), which 
examined all recorded deaths from February 2012–Jan 
2013, 276 possible asthma deaths were considered in 
detail by the confidential enquiry panels. One the key 
findings was that in both primary and secondary care 
only 16% of patients were judged to have good care, with 
46% of deaths being avoidable [2].
One of the key recommendations of the NRAD report 
is that all patients receive a structured annual review 
which assesses asthma control [2]. NICE recommends 
that asthma control should be monitored at every review, 
using a validated questionnaire such as the Asthma 
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Control Test (ACT) in adults and with children over 
5 alongside spirometry or peak flow variability testing 
[3]. The ACT contains 5 questions that are related to 
the frequency of both asthma symptoms and use of 
reliever medication in the previous 4  weeks. The scores 
in the ACT range from 5 (worst control) to 25 (complete 
control). Developmental studies have established 
the cut off points for controlled asthma (ACT, ≥ 20 
points), not well controlled asthma (ACT, ≤ 19 point) 
and uncontrolled asthma (ACT, ≤ 15 points). Readings 
between 20 and 25 prompt a clinician to continue 
the current treatment plan or consider a step down 
in treatment [4]. Studies suggests that both patients 
and clinicians overestimate the degree of asthma 
control—which can result in a failure to make necessary 
interventions such as medication titration, increasing 
the chance of disability and death [5]. Despite this fact 
NICE advises against using FeNO testing to monitor 
asthma control but suggests FeNO can be considered 
as an option to support asthma management in people 
who are symptomatic despite using ICS [3]. This 
recommendation is largely based on evidence from a 
meta-analysis conducted by the Cochrane airways group, 
including 4 moderate to high quality studies in over 700 
participants including both adults and children. This 
examined tailoring treatment with FeNO results vs other 
methods (primarily clinical symptoms). The study shows 
that there was an overall reduction in daily dosing of ICS 
in adults, but not children, and there was no difference 
between groups in all other outcomes including  FEV1 
and asthma exacerbations [6]. More recent evidence 
shows more promising results for the use of FeNO in 
monitoring asthma: a large real-world study in the US 
of nearly 8000 patients compared the management plans 
of patients’ who have had both clinical assessment of 
their asthma control and FeNO levels. The study was 
conducted by asthma specialists, including allergists and 
pulmonologists, but not primary care physicians. Clinical 
assessment was concordant with FeNO testing in only 
56% of cases. FeNO testing also resulted in alterations in 
prescription of ICS in 90% of cases [7].
Methods
Study design and study population
A retrospective observational study in a Central London 
GP Surgery. The Surgery has a total asthma register of 
489 adults and children, and 80% of these patients are 
seen for an annual review each year. The practice has a 
multiple disciplinary team managing asthma including; 
Doctors, Nurses, Physician Associates and Clinical 
Pharmacists. Spirometry is conducted routinely for 
diagnosis of asthma but is not routinely conducted 
at each annual review. The existing practice was to 
conduct a symptom-based assessment of a patient’s 
asthma control using the ACT. FeNO testing was newly 
implemented in 2018 to complement the existing 
methods of diagnosis and monitoring asthma. The 
study was designed to assess the impact of the early 
implementation of this new technology in the primary 
care setting. A review was planned after the first batch of 
tests (100 tests). When measuring FeNO (NIOX VERO, 
Aerocrine AB, Solna, Sweden) the NICE guidelines cut-
off of 40  ppb (parts per billion) for adults and 35 ppbs 
for children are used to confirm a diagnosis of asthma 
[3]. NICE gives no specific guidance on values of FeNO 
for monitoring of asthma, however GINA indicates that 
evidence of residual Type 2 airways inflammation is seen 
with a FeNO of 20 ppb—therefore this cut off is used to 
prompt a step up or step down in treatment [1].
Data collection
A fixed data collection template was used to collect 
participant; Age, Gender, FeNO concentration, ACT 
score, current ICS dose, change in treatment made. The 
current dose of ICS was recorded as; ICS only, low dose 
combination, medium dose combination and high dose 
combination. Change in treatment was recorded as; no 
change, increase in ICS or decrease in ICS.
Only retrospective data was used and no patient 
identifiable data was recorded on the data collection 
template.
Statistical analysis
Statistical Package for the Social Sciences (SPSS Version 
23, USA) was used for statistical analysis. Statistical 
significance was assumed if p < 0.05. A Shapiro–Wilk test, 
established that the data was not normally distributed 
so a Spearman correlation was used to estimate the 
direction and strength of the correlation between the 
two groups. An independent samples t test was used for 
pairwise comparisons.
To estimate the concordance between ACT and FeNO 
measures in their prompt to make changes in the patient’s 
medication, the measures were grouped according to 
following logic: FeNO concentration greater than 20 ppb 
prompts the clinician to increase ICS dosage; similarly, 
an ACT value lower than 20 prompts the same. Actual 
ACT and FeNO measures were merged into two groups 
depending on whether they prompt an increase or not. 
The distribution of the derived variables was compared 
using a Chi square test, and a Kendall’s tau statistic was 
used to calculate the concordance between the measures. 
Lastly, the frequency of a medication increase was 
compared between groups of patients having different 
current medication level using a Chi square test.
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Results
A total of 65 patient who had received both the ACT 
and FeNO as part of their asthma annual review were 
identified. A retrospective notes review of all these 
patients was conducted, with the mean age of 41  years 
(mean ± SD shown, range 4 to 93). Visual inspection 
of boxplots (see Figs.  1  and 2) revealed that there were 
several outlying values in both measures (ACT and 
FeNO) that could also affect the results of correlation 
analysis if based on the parametric Pearson’s correlation. 
Therefore, a Spearman correlation was computed which 
showed a small positive but statically non-significant 
correlation coefficient (ρ = 0.195, p = 0.120).
Around 29% (19 of 65) of patients were not prescribed 
ICS, while more than two-thirds of the patients (46 of 
65, 71%) were prescribed ICS as part of their treatment 
plan (Table  1). Of these 46 patients 29% (n = 19) were 
prescribed a medium or high dose combination, 
25% (n = 16) low dose combination and 17% (n = 11) 
standard ICS dose only. There was only one patient who 
was currently on a high dose combination inhaler and 
therefore was added to ‘medium/high dose combination’ 
group. Over one half of the patients had an increase in 
dosage after ACT and FeNO tests (n = 36, 55%) and 43% 
(n = 28) did not change their treatment, with one patient 
receiving a decrease in the dosage (Table 1).
The asthma control level measured by FeNO ranged 
from 8 to 279  ppb with a median of 26 compared with 
the mean ± SD, 35 ± 39 (Fig. 1a). The median for the ACT 
score is 21 compared to the mean of 20 ± 5, range (5–25) 
(Fig.  1b). There was no correlation between gender 
and age except in females where there was a positive 
correlation between ACT and FeNO scores (ρ = 0.539, 
p = 0.004, n = 26).
To compare the frequency of FeNO and ACT 
prompting an increase in medication, both measures 
were merged into two groups according to the rule that 
a FeNO of 20  ppb and higher prompts an increase in 
medication and an ACT level lower than 20 prompts the 
same. FeNO prompts an increase in dosage more often 
than ACT level (66% n = 43, compared to 42%, n = 27) 
(p = 0.005, Χ2 test), thus FeNO testing has a significant 
impact on ICS prescribing.
The concordance of these two measures in prompting 
an increase in medication was estimated by making a 
cross tabulation of the overall share each combination 
made (Table  2). In one-third of the cases (n = 21, 32%), 
both measures showed the same prompts: in 8 cases 
(12%) both did not prompt an increase and for 13 
cases (20%) both measures prompted an increase in 
medication. Almost half of the cases (n = 30, 46%) should 
have had an increase in medication based on their FeNO 
Fig. 1 A box-plot of FeNO levels. The median is shown with 25–75th 
percentile. An outlier of 279 is included in the analysis but not shown
Table 1 Demographic characteristics of the participants
Categorical variables Count Percent
Gender
 Male:Female 39:26 60:40
ICS dose
 None 19 29.2
 Standard ICS only 11 16.9
 Low dose combination 16 24.6
 Medium/high dose combination 19 29.2
Change in treatment
 Decrease 1 1.5
 No change 28 43.1
 Increase 36 55.4
Fig. 2 Box plot of ACT scores
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levels, but not based on their ACT level. Vice versa 
about one-fifth of the sample (n = 14, 21.5%) should 
had an increase based on their ACT level, but not based 
on FeNO levels. The concordance between these two 
measures is negative and low (Kendall’s tau-b correlation: 
τb = − 0.321, p = 0.010).
Changes in treatment by current medication type are 
shown with a lower proportion of cases receiving an 
increase dosage in those receiving combination inhalers 
(p < 0.001) (Table 4).
Conclusion
The primary study objective was to assess the correlation 
between patient’s self-reported asthma symptoms 
as measured by the Asthma Control Test (ACT) and 
the Fractional Exhaled Nitric Oxide level (FeNO) in a 
primary care setting. Notes from 65 asthma sufferers 
were reviewed who had received both FeNO and ACT 
as part of their asthma annual review. It is assumed that 
the patient’s self-reported symptoms are an accurate 
representation of airways inflammation; therefore a 
high FeNO level should accompany a low ACT score. 
However, in this study there was no correlation between 
FeNO and ACT scores (ρ = 0.195, p = 0.120). This data 
contradicts Stern et al. who retrospectively analysed data 
from the Childhood Asthma Respiratory Inflammatory 
Status Monitoring (CHARISM) study, a prospective, 
open-label, randomized, multicentred, parallel-group 
study in Italy and The Netherlands [8]. Data was 
extracted on daily FeNO values and symptom scores 
over 192  days in 41 children with mild to moderate 
atopic asthma. The study shows that the majority of 
subjects had the strongest positive relationship between 
FeNO values and symptom scores on the same day. 
Subjects who had severe or moderate exacerbations had 
a stronger positive cross-correlation between FeNO 
values and symptom scores, suggesting that concordance 
of FeNO values and symptom scores is an indicator of 
increased risk of exacerbation. Stern et  al. examined 
a very specific population in their study, whereas this 
study covers a much broader age range of patients and 
therefore a wide range of asthma phenotypes [8]. The 
concept of concordance between FeNO values and 
symptom scores has recently been advocated through 
phenotype-cluster analysis of an asthmatic cohort [9]. It 
has been found that within a group of adult asthmatic 
patients, there are subjects in whom FeNO values are 
strongly associated with asthma symptoms, whereas 
in others this relationship is weak. This establishes the 
concept of “concordant” and “discordant” phenotypes 
of asthma. Cross-correlation analysis of biomarkers and 
symptoms fluctuating over time might be a new way of 
quantifying such concordance and might help to identify 
new “fluctuation phenotypes” of asthma. Crucially Stern 
et  al. suggest that those patients with discordant FeNO 
values and asthma symptoms may gain the most benefit 
from more regular FeNO monitoring as it may be the 
best independent predictor of an exacerbation [8].
The level of association in this study was assessed 
within the individual demographic groups to ascertain 
if the association was differently skewed or statistically 
stronger in the same direction (Table 3). There was only 
one statistically significant relationship between the two 
variables and that was a positive correlation between 
FeNO and ACT amongst females (ρ = 0.539, p = 0.004). 
This would suggest that there may be a difference in 
symptom perception in males and females, although 
this should be judged with caution given the sample size 
(n = 26).
A secondary analysis was performed to assess the 
relationship between FeNO and ACT and a change 
in medication (only no change and an increase in 
medication) was considered. The analysis shows that both 
FeNO and ACT are both statistically significantly higher 
among patients who had an increase in their dosage, 
t(62) = − 4.193, p < 0.001 and t(62) = − 2.259, p = 0.027, 
respectively. When split into two groups according to the 
following assumption; an ACT level below 20 or a FeNO 
concentration of 20 prompts a clinician to increase ICS 
dosage, the analysis shows that FeNO prompted a step 
Table 2 FeNO and  ACT concordance in  prompting 
of dosage change
ACT does not prompt 
an increase
ACT prompt 
an increase
n Table % n Table %
FeNO does not 
prompt an 
increase
8 12.3 14 21.5
FeNO prompt an 
increase
30 46.2 13 20.0
Table 3 Correlation analysis results (overall, by  sex 
and age groups)
a Marks a significant correlation at 99% confidence interval
FeNO * ACT 
correlation
p-value N
Overall 0.195 0.120 65
Male − 0.244 0.134 39
Female 0.539a 0.004 26
Less than 40 years old 0.037 0.837 33
40 years old and higher 0.282 0.117 32
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up (p = 0.05) in medication more often than ACT did 
(n = 43, 66% compared to n = 27, 42%). Almost half of the 
patients (n = 30, 46%) are prompted to have an increase 
in medication based on their FeNO levels, but not based 
on their ACT score. Vice versa about one-fifth of the 
sample (n = 14, 22%) would have an increase in their ICS 
dose based on their ACT score, but not based on FeNO 
level. This parallels the findings seen in a secondary/
tertiary care setting by Hanania, Massanari and Jain [7]. 
These authors asked clinicians to rate the level of airways 
inflammation as low, intermediate or high using clinical 
measures that were conventionally available to them 
including: pulmonary function tests, asthma symptoms, 
control questions and respiratory examinations. 
Clinicians recorded any changes in medications that 
would be made according to their clinical assessment, 
this was then repeated following measurement of FeNO 
where airways inflammation was recategorized according 
to the ATS cut-off points for low (< 25 ppb), intermediate 
(25–50 ppb), and high (> 50 ppb) and clinicians indicated 
whether their treatment strategy would change armed 
with this new information. The data show that clinical 
assessment matched FeNO classification in only slightly 
more than half the patients (4457 of 7901 56.4%). 
Subgroup analysis showed that in the high inflammation 
subgroup (FeNO > 50  ppb), clinician’s assessment 
matched the FeNO category in only one-third of patients 
(341 of 1016 33.6%).
When assessing the impact on ICS prescribing; it is 
seen that FeNO prompted an increase in medication 
to commence ICS in 100% of patients who were not 
currently taking an ICS (Table 4). This is consistent with 
the BTS guidelines which recommend that all patients 
diagnosed with asthma and those with an intermediate 
probability of asthma are commenced directly onto a 
low dose ICS [10]. It also recommends that due to very 
limited side-effects from long term use of low dose ICS, 
patients should be maintained on these. This is contrary 
to NICE which recommends that a SABA may be offered 
to adults and children newly diagnosed with asthma 
and may be continued alone in all patients who have 
infrequent, short-lived wheeze and normal lung function 
[3].
The study suggests that FeNO is a superior method of 
assessing underlying airways inflammation compared 
to patients self-reported symptoms as measured by the 
ACT. This substantiates the observation that chronic 
airways inflammation persists despite lung function 
tests returning to normal and in the absence of self-
perceived symptoms [11]. Guidance which does not 
support the use of FeNO as a monitoring tool in asthma, 
has largely considered data which looks at FeNO as a 
direct reflection of eosinophilic inflammation. Shaw 
et  al. enrolled 118 participations with a primary care 
diagnosis of asthma and randomised to single-blind trial 
of ICS based on FeNO measurement or standard step 
up and down according to BTS guidance [10, 12]. They 
showed no statistically significant reduction in asthma 
exacerbations or ICS dosage. Their cut-off for adjustment 
of therapy was set at 26  ppb for an increase in ICS 
and 16  ppb or less than 26  ppb on two occasions for a 
reduction in ICS. These cut-offs were chosen as they were 
thought to most accurately identify a sputum eosinophil 
count of greater than 3% or less than 1% respectively, but 
these cut-offs may not accurately reflect the underlying 
airway inflammation [13].
Limitations of study
The sample size was limited to 65, as this study was 
conducted to capture the impact of FeNO testing 
following initial implementation. The study, however, 
covers both genders, a broad age range and the GP 
surgery is based in a multicultural area with varying 
socio-economic backgrounds. Another limitation is 
the use of the ACT in the age range of the population 
included (4 to 93 years old), the standard ACT was used 
for all patients, with significant input from parents for 
younger children. There is however a specific childhood 
Asthma Control Test (C-ACT) that is validated for use 
with children 4–11  years old [14]. A standard ACT is 
used in regular practice at the study site: when children 
are too young to answer the questions, the questions 
Table 4 Change in treatment by current medication type
As there was only single case with a decreased medication dosage, it was excluded from the analysis. The difference in the distribution is statistically significant as 
assessed by Chi square test (χ2(3) = 23.006)
ICS dosage
None ICS only Low dose combination Medium/high 
dose combination
n % n % n % n %
No change in treatment 0 0.0 5 45.5 10 62.5 13 72.2
Increase in dosage 19 100.0 6 54.5 6 37.5 5 27.8
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are answered by the adults accompanying them to the 
appointment. The accuracy of the result is significantly 
reduced when the guardian who accompanies the child 
does not have a detailed knowledge of the child’s asthma. 
The ACT and c-ACT both suffer from this problem, 
but this is more pronounced in the ACT as there are no 
specific questions tailored for younger children to answer. 
The study does not assess the impact of any adjustments 
made in therapy and the longer-term impact on asthma 
care, such as rates of exacerbation; as this was an initial 
assessment of early implementation of a new technology 
to the primary care setting. A further prospective study 
with matched controls following participants over 1 year, 
would help to elucidate this.
Clinical application
Within a financially pressurised National Health Service 
the cost burden of implanting a new technology to 
monitor asthma must be taken into consideration. FeNO 
is currently recommended by NICE for the diagnosis 
of Asthma and suggests that diagnostic hubs could 
be established in order to achieve economies of scale 
and improve the practicalities of implementing this 
recommendation in primary care [3]. The evidence from 
this study shows that there would also be an increase 
in use and therefore cost of medication if FeNO was 
introduced for monitoring of asthma. 100% patients 
(n = 19) naive to ICS were commenced on treatment and 
55% (n = 36) of the total number of patients had a step up 
in their treatment. Only one patient in this study had a 
reduction (step-down) in their treatment, a larger study 
may show the greater impact of stepping down and the 
costs associated with this. Overall the greatest healthcare 
costs come from Accident and Emergency (A&E) 
attendances, hospital inpatient admissions and ITU 
admissions and these result from acute exacerbations 
[15]. Understanding whether monitoring asthma using 
FeNO prevents exacerbations, would help confirm the 
longer-term cost benefits of FeNO use. The evidence 
to date on this has been mixed but has been examined 
in two Cochrane reviews one in adults and one in 
children. The former evaluated the efficacy of tailoring 
asthma interventions based on FeNO, in comparison to 
not using FeNO, that is management based on clinical 
symptoms (with or without spirometry/peak flow) or 
asthma guidelines or both, for asthma‐related outcomes 
in adults [6]. Seven studies with over 1500 participants 
were included; the FeNO group had a lower rate of 
exacerbations compared to controls (rate ratio 0.59, 95% 
CI 0.45 to 0.77), however there was no difference between 
the groups for exacerbations requiring hospitalisation 
or rescue oral corticosteroids. For this reason, the 
authors stated that FeNO could not be recommended 
universally amongst all adult asthma patients, however 
the intervention may be useful in those adults with 
frequent exacerbations. A meta-analysis with the same 
objective was conducted by the same group in children 
[16]. The review included nine studies of over 1300 
children; there was a significant difference in the number 
of children having one or more asthma exacerbations 
over the study period, and this was significantly lower 
in the FeNO group in comparison to the control group 
[odds ratio (OR) 0.58, 95% confidence interval (CI) 0.45 
to 0.75; 1279 participants; 8 studies]. The number of 
children in the FeNO group requiring oral corticosteroid 
courses was lower in comparison to the children in the 
control group, but there was no statistically significant 
difference between the groups for exacerbations 
requiring hospitalisation. The authors concluded again 
that monitoring with FeNO may be beneficial in a subset 
of children but could not be recommended universally 
for monitoring of all children with asthma.
If we consider the model of implementing a diagnostic 
Hub in primary care (covering a federation of GP 
surgeries or covering a whole Clinical Commissioning 
Group (CCG) depending on the geographical size of the 
CCG) it would be impractical for every patient to receive 
a FeNO test at their asthma annual review. A referral 
system would need to be in place and this could risk 
stratify patients to receive the test. Patients who may be 
suitable for FeNO monitoring could include: any patients 
with a confirmed diagnosis of asthma (by FeNO or other 
means) who are not currently taking an ICS, adults who 
report symptoms despite being treated with medium/
high dose ICS, children who are symptomatic despite 
treatment with any level of ICS, adults and children with 
a history of exacerbations. This could have an impact in 
both adults and children, but the greatest impact may 
be seen in younger children where peak flow diaries and 
spirometry are difficult to conduct.
When FeNO was first introduced in the surgery, there 
was not a strict criteria for use of the test, as the clinical 
staff become familiar with the test and established 
the benefit of use. FeNO is currently unfunded by our 
local CCG and the cost based on the number of tests 
performed in the surgery is relatively high. The outcome 
of this study could help to create a selection criterion for 
patients who should receive the test.
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